Navigation Links
Conference on developing new treatments for Tourette Syndrome

A conference is being organized at Washington D.C. on September 10, 11&12, by Yale School of Medicine. Several prominent scientists from Yale and other institutes will// meet to discover new ways to treat Tourette Syndrome (TS), a familial neurological disorder that begins in childhood and is characterized by chronic motor and vocal tics.

The characteristics of TS are blinking, facial movements, head jerking, throat clearing, coughing, grunting, and other brief noises. TS is not life threatening, but it can cause social isolation, particularly in children.

The chairperson of the forthcoming conference on identifying new treatments for TS, is Lawrence Scahill, professor of nursing and child psychiatry at Yale. Scientists from and outside the TS domain, will come together to discuss the latest findings in neuroscience to improvise the current treatment for tics.

"We have assembled a group of experts across a range of basic science and clinical fields who probably would not otherwise interact with each other," Scahill said. "By the end of the conference we hope to have new directions for the treatment for TS."

Over the past decade there has been a convergence of evidence from neuroimaging, neuropathology, genetics, and behavioral neuroscience about the neurobiology of TS. However, these advances have not yet had much impact on treatment. Research projects at Yale and at several other centers around the world are actively testing various treatments for TS, but new approaches are needed.

Once considered a rare and severe disorder, TS is now viewed as a disorder that ranges from mild to severe, affecting an estimated six of every 1,000 school-age children. Although many children will show a mild variant of TS, as many as one child in 1,000 in the United States may have tics that interfere with every day living.

The most effective medications are antipsychotic drugs with potent dopamine blocking pr operties. These medications, however, may be associated with sedation, weight gain, and neurological effects. Other types of medications have been used with variable results. "Clearly, it is time for recent findings from cutting edge neuroscience to inform new treatments for TS," Scahill said.

(Source: Eurekalert)
'"/>




Related medicine news :

1. International Conference On Malaria - Laveran To Genomics
2. African Conference to Combat AIDS
3. 5th European Breast Cancer Conference Talks about Everything from Patient to Oncologist
4. Consultation Conference to control HIV, TB and Malaria
5. Afghanistan Hosting A UN Funded Regional Health Conference
6. New Delhi to Host Conference on Accident & Emergency Medical Treatment
7. UN Conference Calls For Monitoring System To Check Bird Flu
8. National Autism Conference In US Expected To Draw Thousands In Attendance
9. Ayurvedic Treatment to be Focus of Conference
10. Health Ministers Conference on July 30
11. XVI International AIDS Conference To Be Held In Toronto In August
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... New York, NY (PRWEB) , ... April 28, ... ... Shiel Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast ... indicates recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery and ... revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, with ... revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional back ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The Texas ... in recently to the labor and delivery team at Women’s Hospital at Renaissance in ... who give birth at the hospital and decide to donate. , “Women’s Hospital ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... hERG liability could substantially improve drug safety and minimize the cost of development. ... validating ion channel inhibition using cell lines and for cardiac toxicity using induced ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
Breaking Medicine Technology: